Regenxbio.gcs-web.com

Regenxbio.gcs-web.com has server used 104.126.208.13 (United States) ping response time Hosted in Akamai Technologies, Inc. Register Domain Names at CSC Corporate Domains, Inc.. This domain has been created 5 years, 91 days ago, remaining 2 years, 273 days. You can check the 0 Website and blacklist ip address on this server

Domain information

Registrar WHOIS Server: whois.corporatedomains.com

Registrar URL: http://cscdbs.com     See All 0+

Creation Date: 2016-07-22 5 years, 91 days

Updated Date: 2019-09-13 2 years, 40 days ago

Expiry Date: 2024-07-22 2 years, 273 days left     See All

  Sign up for notifications near expiration

Registrar: CSC Corporate Domains, Inc.

Abuse Email: [email protected]

Abuse Phone: 8887802723

  Full details

Top 10 Hosting Providers

Registrar URLDomain CountsRegistrar NameAbuse Email
www.godaddy.com2,280,668GoDaddy.com, LLC[email protected]
www.tucows.com535,579Tucows Domains Inc.
networksolutions.com526,027Network Solutions, LLC[email protected]
www.namecheap.com333,839NameCheap, Inc.[email protected]
www.enom.com299,925eNom, LLC
www.publicdomainregistry.com294,948PDR Ltd. d/b/a PublicDomainRegistry.com[email protected]
www.whois.godaddy.com174,077GoDaddy.com, LLC[email protected]
www.fastdomain.com161,753FastDomain Inc.[email protected]
www.ionos.com159,2071&1 IONOS SE[email protected]
www.networksolutions.com149,653Network Solutions, LLC[email protected]

Full view & Download

Keywords Suggestions

Gcs webmail

Gcs webmail login

Gcs website

Gcs-web

( Please select at least 2 keywords )

See More:   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z  

› Arrival rock hill sc

› Arrival spac investor presentation

› Gweb information system

› Gcs web portal

› Kohl's investor relations

› Arrival investor presentation

› Aramark investor relations

› Gcs webmail

Hosting Provider

NetName: AKAMAI

Organization: Akamai Technologies, Inc.     See All 10,087+

Provider URL: Akamai.com

Hostname: a104-126-208-13.deploy.static.akamaitechnologies.com

IP Server: 104.126.208.13 Reg: 2014-04-22, Updated: 2014-04-22

Blacklist: Check Backlist Status

Country: United States

Address: 145 Broadway, Cambridge, MA 02142, US

Latitude: 42.362598

Longitude: -71.084297

Name Server:

  • NS-1276.AWSDNS-31.ORG
  • NS-1561.AWSDNS-03.CO.UK
  • NS-158.AWSDNS-19.COM
  • NS-682.AWSDNS-21.NET

Abuse Email: [email protected]

Abuse Phone: +1-617-444-0017

Top 10 Hosting Providers

Website URLDomain CountsOrganizationAbuse Email
Google.com681,421Google LLC[email protected]
Godaddy.com650,706GoDaddy.com, LLC[email protected]
Cloudflare.com637,900Cloudflare, Inc.[email protected]
Endurance.com488,827The Endurance International Group, Inc.[email protected]
Amazon.com439,891Amazon Technologies Inc.[email protected]
297,405Domain Name Services
Amazonaws.com287,121Amazon Technologies Inc.[email protected]
Liquidweb.com159,971Liquid Web, L.L.C[email protected]
Squarespace.com150,667Squarespace, Inc.[email protected]
Ripe.net128,362RIPE Network Coordination Centre[email protected]

Full view & Download

List of found email addresses

No Emails Found

Find Websites hosted

There are no results for IP: 104.126.208.13

Port Scanner (IP: 104.126.208.13)

Shareholder Services

  • You may automatically receive REGENXBIO financial information by e-mail
  • To choose your options for e-mail notification, please select your options and enter your e-mail address below and click Submit
  • To change your e-mail options at any time, re-enter your e-mail …

Regenxbio.gcs-web.com   DA: 21 PA: 38 MOZ Rank: 59

Contact Us – REGENXBIO

  • United States Afghanistan Albania Algeria American Samoa Andorra Angola Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei

Regenxbio.com   DA: 13 PA: 12 MOZ Rank: 26

REGENXBIO – The Leader In AAV Gene Therapy

  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy
  • Our gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease.

Regenxbio.com   DA: 17 PA: 17 MOZ Rank: 36

SIGN UP TO JOIN – REGENXBIO

  • REGENXBIO- is committed to serving the communities affected by the disorders for which we are developing treatments
  • By signing up below, we will do our best to keep you informed on our relevant program (s) and will try to tailor communications to best address your individual needs

Regenxbio.com   DA: 13 PA: 14 MOZ Rank: 30

REGENXBIO Presents Positive

  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy
  • REGENXBIO's NAV ® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.

Regenxbio.gcs-web.com   DA: 21 PA: 50 MOZ Rank: 75

Corporate Governance

  • 9804 Medical Center Drive, Rockville, MD 20850 240.552.8181

Regenxbio.gcs-web.com   DA: 21 PA: 32 MOZ Rank: 58

REGENXBIO Announces RGX-314 Data

  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy
  • REGENXBIO's NAV ® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.

Regenxbio.gcs-web.com   DA: 21 PA: 50 MOZ Rank: 77

About Us – REGENXBIO

  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy
  • Our gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease

Regenxbio.com   DA: 13 PA: 10 MOZ Rank: 30

MPS I – REGENXBIO

  • Mucopolysaccharidosis Type I (MPS I) is a rare genetic disease caused by a mutation in the gene responsible for making human α-l-iduronidase (IDUA), an enzyme needed by cells to break down long chains of sugar molecules known as mucopolysaccharides

Regenxbio.com   DA: 13 PA: 7 MOZ Rank: 28

CLN2 – REGENXBIO

Late-infantile neuronal ceroid lipofuscinosis Type 2 (or CLN2 disease), one of the most common forms of Batten disease, is a rare genetic disorder caused by a mutation in the gene that is responsible for making tripeptidyl peptidase (TPP1), an enzyme needed to break …

Regenxbio.com   DA: 13 PA: 6 MOZ Rank: 28

REGENXBIO Announces Closing Of

  • 12, 2021 /PRNewswire/ -- REGENXBIO Inc
  • (Nasdaq: RGNX) today announced the closing of its previously announced underwritten public offering of 4,260,000 shares of its common stock at a price to the public of $47.00 per share, as well as the exercise in full of the underwriters' option to purchase 639,000 additional shares at the public offering price.

Regenxbio.gcs-web.com   DA: 21 PA: 50 MOZ Rank: 81

Log In To Canvas

Forgot Password? Enter your SSC Network User Name and we'll send you a link to change your password.

Online.seminolestate.edu   DA: 24 PA: 11 MOZ Rank: 46

Regenexbio, IncGood Medicine For Your Portfolio

  • Regenxbio has a market capitalization of $1.4 billion and an enterprise value of approximately $1 billion
  • The company has approximately $400 million in cash and cash equivalents at the end of 2019 with sales of about $35 million for the year
  • Consequently, it lost about $94 million, the result of $124 million research and development expenses

Sickeconomics.com   DA: 21 PA: 30 MOZ Rank: 63

REGENXBIO Announces Pricing Of

  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy
  • REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.

Regenxbio.gcs-web.com   DA: 21 PA: 50 MOZ Rank: 84

REGENXBIO Reports Second Quarter

  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy
  • REGENXBIO's NAV ® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.

Regenxbio.gcs-web.com   DA: 21 PA: 50 MOZ Rank: 85

Акции REGENXBIO RGNX – котировки, график стоимости акций

  • Источник: regenxbio.gcs-web.com 06.05.2021 Убыток Regenxbio по GAAP за 3 мес
  • составил $50,139 млн., увеличившись на 25,2% по сравнению с $40,038 млн
  • в предыдущем году.

Blackterminal.ru   DA: 16 PA: 18 MOZ Rank: 49

Privacy Policy – REGENXBIO

  • Cookies are uniquely assigned to your browser and can only be read by a web server in the domain that issued the cookie to you
  • Cookies cannot be used to run programs or deliver viruses to your computer
  • “REGENXBIO” “we” or “us” means REGENXBIO Inc
  • REGENXBIO is the data controller of the Personal Information collected under this

Regenxbio.com   DA: 17 PA: 16 MOZ Rank: 49

REGENXBIO Announces Closing Of Public Offering Of Common

  • 14, 2018 /PRNewswire/ -- REGENXBIO Inc
  • (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price …

Regenxbio.gcs-web.com   DA: 21 PA: 50 MOZ Rank: 88

Rocket Pharmaceuticals And REGENXBIO Announce New License

Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2017 and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S

Rocketpharmaceuticals.gcs-web.com   DA: 33 PA: 50 MOZ Rank: 32

Company REGENXBIO News, Employees And Funding Information

  • REGENXBIO is the leading next-generation AAV gene therapy company, developing a new class of personalized therapies based on its proprietary NAV Technology platform for a range of severe diseases with serious unmet needs
  • NAV Technology includes novel AAV vectors AAV7, AAV8, AAV9, and AAVrh10
  • In addition, together with Fidelity Biosciences, REGENXBIO formed Dimension …

Topionetworks.com   DA: 21 PA: 45 MOZ Rank: 85

Hunter Syndrome Foundation

  • regenxbio.gcs-web.com REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights | REGENXBIO Inc
  • - RGX-314 subretinal pivotal wet AMD trial expected to initiate in Q1 2021 - Enrollment continues in RGX-314 suprachoroidal Phase II AAVIATE study; initial safety data expected in early 2021 - RGX-314 suprachoroidal Phase II

Facebook.com   DA: 16 PA: 31 MOZ Rank: 67

ReGenX Biosciences VentureRadar

  • is the leading next-generation AAV gene therapy company, developing a new class of personalized therapies based on its proprietary NAV™ Technology platform for a range of severe diseases with serious unmet needs
  • NAV Technology includes novel AAV vectors AAV7, AAV8, AAV9, and AAVrh10.

Ventureradar.com   DA: 20 PA: 50 MOZ Rank: 91

Regenxbio Company Profile

  • Regenxbio has 257 employees at their 1 location and $154.57 M in annual revenue in FY 2020
  • See insights on Regenxbio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Craft.co   DA: 8 PA: 10 MOZ Rank: 40

RegenxBio Inc: A Compelling Investment Opportunity!

  • RegenxBio, Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company which is cementing its place as a global leader in gene therapies, targeting the treatment of retinal, metabolic, and neurodegenerative diseases
  • The Company is leveraging a proprietary NAV Technology Platform to develop a pipeline of candidates that utilize adeno-associated viral vectors (AAV) viral vectors, …

Aviseanalytics.com   DA: 22 PA: 50 MOZ Rank: 95

Regenxbio, Stung By Trial Hold On Gene Therapy, Sues FDA

  • Dive Brief: Regenxbio, facing regulatory delays for two of its gene therapy programs, has sued the Food and Drug Administration in hopes of overturning the agency's decision to halt enrollment into one study and stop dosing in a second.; The lawsuit, filed Nov
  • 7 in federal district court, argues the FDA violated its own regulations in issuing the clinical hold orders and caused reputational

Biopharmadive.com   DA: 21 PA: 50 MOZ Rank: 95

Working At REGENXBIO

  • Based in Rockville, MD, REGENXBIO is a small health care company with only 107 employees and an annual revenue of $8.8M
  • To transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company's NAV Technology Platform.

Zippia.com   DA: 14 PA: 24 MOZ Rank: 63

News & Events

  • REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call
  • AbbVie and REGENXBIO Announce Eye Care Collaboration
  • REGENXBIO to Participate in Upcoming Investor Conferences
  • Jean Bennett and George Migausky Join REGENXBIO Board of Directors

Ir.regenxbio.com   DA: 16 PA: 16 MOZ Rank: 58

Regenxbio Expects Selection Of Lead Product Candidate In

  • REGENXBIO expects to select a lead product candidate in the first half of 2020 and provide a program update in the second half of 2020
  • REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.

Haei.org   DA: 8 PA: 50 MOZ Rank: 85

REGENXBIO INC Share Price

  • As of 15/10/21, shares in Regenxbio Inc are trading at $35.95, giving the company a market capitalisation of £1.11bn
  • This share price information is delayed by 15 minutes
  • How has the Regenxbio Inc share price performed this year? Shares in Regenxbio Inc are currently trading at $35.95 and the price has moved by 27.12% over the past 365 days.

Stockopedia.com   DA: 19 PA: 37 MOZ Rank: 84

Building Out A Cara Community Biotech 50

  • Building out a Cara Community Biotech 50
  • On August 7, I published an article on the CC Biotech 25, noting there were many more peer group companies that I had wanted to add to the list
  • When time is available, I will summarize each company and, along with the CC Goldminer 50, I will set

Billcara.com   DA: 16 PA: 50 MOZ Rank: 95

Recently Analyzed

1: Visitxalapa.com 1 seconds ago

2: Pissedconsumer.com 1 seconds ago

3: Simplyhealthyflorida.com 0 seconds ago

4: Warroomdefense.com 0 seconds ago

5: Online-domain-tools.com 0 seconds ago

6: Mercy.net 2 seconds ago

7: Baypeds.com 0 seconds ago

8: Edcomm.com 1 seconds ago

9: Besthealthnutritionals.com 3 seconds ago

10: Ganji.com 15 seconds ago

Tool Checker

Domain Expiry Date Updated

Expiry DateExpiry DateDomain ProviderHosting Provider
Ganji.com1 year, 316 days leftAlibaba Cloud Computing (Beijing) Co., Ltd.Tencent cloud computing (Beijing) Co., Ltd.
Besthealthnutritionals.com 88 days leftGoDaddy.com, LLCAmazon Technologies Inc.
Edcomm.com1 year, 133 days leftNetwork Solutions, LLC1&1 IONOS Inc.
Baypeds.com4 years, 190 days leftRegister.com, Inc.GoDaddy.com, LLC
Mercy.net 137 days leftTLDS L.L.C. d/b/a SRSPlusSisters of Mercy Health System
Online-domain-tools.com 349 days leftGransy, s.r.o.RIPE Network Coordination Centre
Warroomdefense.com 123 days leftGoDaddy.com, LLCAmazon Technologies Inc.
Simplyhealthyflorida.com 104 days leftTucows Domains Inc.PrivateSystems Networks
Pissedconsumer.com 14 days leftGoDaddy.com, LLCAmazon Technologies Inc.
Visitxalapa.com 278 days leftDomainSpot LLCNew Dream Network, LLC

<< See All >>

.COM - 10,595,200+   .ORG - 1,117,549+   .EDU - 123,500+   .NET - 792,945+   .GOV - 30,232+   .US - 84,439+   .CA - 122,904+   .DE - 220,061+   .UK - 272,390+   .IT - 108,882+   .AU - 152,812+   .CO - 51,739+   .BIZ - 59,081+   .IO - 32,494+   .NL - 99,647+   .SG - 19,713+   .INFO - 81,589+   .IE - 26,934+   .ME - 25,076+   .FR - 98,576+   .EU - 61,372+   .RU - 165,043+   .PH - 9,511+   .INT - 1,166+   .IN - 87,021+   .ES - 38,035+   .CZ - 71,869+   .VN - 48,920+   .TV - 14,250+   .SITE - 9,829+   .RO - 37,484+   .PL - 44,520+   .PK - 10,373+   .MOBI - 4,464+   .LK - 5,507+   .CN - 66,137+   .CH - 66,914+   .AT - 31,992+  

Email Address Search | IP Address Blacklist Check | Hosting Providers | Domain Providers | Website Error Checker

© 2018 Site-Stats.org. All rights reserved. Email: [email protected]